Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPLIFY: 64Cu-SAR-bisPSMA PET/CT in Biochemical Recurrence of Prostate Cancer
NCT06970847Phase 3Active, not recruiting
- Sponsor
- Clarity Pharmaceuticals
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of 64Cu-SAR-bisPSMA in prostate cancer (PCa), sponsored by Clarity Pharmaceuticals. Primary endpoint: Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer at 52 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
64Cu-SAR-bisPSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06970847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970847.